Document:

Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[****]”
Exhibit 10.1
​
EXECUTION VERSION
​
CONSENT AND AMENDMENT NO. 3 TO
SECOND AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT
​
This CONSENT AND AMENDMENT NO. 3 TO SECOND AMENDED AND RESTATED
LOAN AND SECURITY AGREEMENT (this “Consent and Amendment”), is dated as of July 30, 2021 and is entered into by and among (a) (i) UNIQURE BIOPHARMA B.V., a private limited liability company incorporated and existing under the laws of the Netherlands, having its corporate seat at Amsterdam, the Netherlands and registered at the trade register of the Chamber of Commerce for Amsterdam under number 34275365 (“uniQure Bio”), (ii) UNIQURE, INC., a Delaware corporation (“US Borrower” and together with uniQure Bio hereinafter collectively referred to as “Borrower”), (iii) UNIQURE IP B.V., a private limited liability company incorporated and existing under the laws of the Netherlands, having its corporate seat at Amsterdam, the Netherlands and registered at the trade register of the Chamber of Commerce for Amsterdam under number 34275369 (“uniQure IP”), and (iv) UNIQURE N.V. (formerly uniQure B.V.), a public limited company incorporated and existing under the laws of the Netherlands, having its corporate seat at Amsterdam, the Netherlands and registered at the trade register of the Chamber of Commerce for Amsterdam under number 54385229 (“uniQure Holdings” and, together with Borrower and uniQure IP, the “Obligors”), (b) HERCULES CAPITAL, INC., a Maryland corporation in its capacity as administrative agent for itself and the Lender (as defined herein) (in such capacity, “Agent”), and (c) the several banks and other financial institutions or entities from time to time parties to the Loan Agreement (collectively, referred to as “Lender”).   Capitalized terms used herein without definition shall have the same meanings given them in the Amended Loan Agreement (as defined below).
​
RECITALS
​
A.WHEREAS, Obligors, Agent and Lender have entered into that certain Second Amended and Restated Loan and Security Agreement, dated as of May 6, 2016, as amended by Amendment No. 1 to Second Amended and Restated Loan and Security Agreement dated as of December 6, 2018, and as further amended by Amendment No. 2 to Second Amended and Restated Loan and Security Agreement dated as of January 29, 2021 (as so amended and as may further be amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Loan Agreement”), pursuant to which Lender has agreed to extend and make available to Borrower certain advances of money;
​
B.WHEREAS, uniQure Holdings has entered into that certain Sale and Purchase Agreement by and among uniQure Holdings (the “Corlieve Sale and Purchase Agreement”), as purchaser, the shareholders of Corlieve Therapeutics SAS, a société par actions simplifiée formed under the laws of France (“Corlieve”) party thereto, as sellers, and the holder representative thereunder, pursuant to which uniQure Holdings will acquire all of the shares of Corlieve (the “Acquisition”);
​
C.WHEREAS, Borrower has requested that (i) Agent and Lender consent to the transactions to be consummated on the “Closing Date” (as defined in the Corlieve Sale and Purchase
Agreement) (such transactions, the “Corlieve Closing Date Transactions”), and (ii) Lender make certain amendments to the Loan Agreement in connection with the Corlieve Sale and Purchase Agreement; and
​
D.WHEREAS, (i) Agent and Lender have agreed to consent to the Acquisition, and (ii) Obligors and Lender have agreed to amend the Loan Agreement, upon the terms and conditions more fully set forth herein.  
​
​
​

1

AGREEMENT
​
NOW THEREFORE, in consideration of the foregoing Recitals and intending to be legally bound, the parties hereto agree as follows:
​
1.CONSENT TO ACQUISITION. Subject to the satisfaction of the conditions specified in Section 5 hereof, Agent and Lender hereby (i) consent to the Acquisition, and (ii) agree, notwithstanding anything to the contrary in Section 7.9 of the Loan Agreement, that the Corlieve Closing Date Transactions are permitted under Section 7.9 of the Loan Agreement.
​
2.AMENDMENTS. In each case subject to the satisfaction of the conditions specified in Section 5 hereof:
​
2.1.Section 1.1 of the Loan Agreement is hereby amended by inserting the following paragraphs in their appropriate alphabetical order therein:
​
““Corlieve Closing Date” means the “Closing Date” as defined in the Corlieve Sale and Purchase Agreement.”
​
““Corlieve Operating Accounts” means one or more Deposit Accounts in France or Switzerland maintained in the name of Corlieve Therapeutics, provided that (a) the aggregate amount on deposit in such Deposit Accounts shall at no time be permitted to exceed €2,500,000 (or the equivalent amount thereof in US Dollars), it being understood and agreed that such amounts may exceed €2,500,000, as a result of cash on the balance sheet of Corlieve Therapeutics as of the Corlieve Closing Date, and (b) amounts on deposit in such Deposit Accounts shall only be used for research and development of the acquired Product (as defined in the Corlieve Sale and Purchase Agreement) and related activities or to make such payments in the ordinary course of business as are required to comply with applicable laws and regulations, including (for the avoidance of doubt) payment of taxes.”
​
““Corlieve Sale and Purchase Agreement” means that certain Sale and Purchase Agreement, dated as of June 21, 2021, by and among uniQure Holdings, each of the shareholders of Corlieve Therapeutics party thereto and the holder representative thereunder, as in effect as of the Third Amendment Effective Date.”
​
““Corlieve Therapeutics” means Corlieve Therapeutics SAS, a société par actions simplifiée formed under the laws of France.”
​
““Free Share Transfer Date” has the meaning given to it in the Corlieve Sale and Purchase Agreement.”
​
““Free Shares” has the meaning given to it in the Corlieve Sale and Purchase Agreement.”
​
““Third Amendment Effective Date” means July 30, 2021.”
​
​

2

2.2.The defined term “Permitted Indebtedness” set forth in Section 1.1 of the Loan Agreement is hereby amended to insert the following clause (xv) in appropriate numerical order as follows and to re-number the existing clauses (xv) and (xvi):
​
“(xv) amounts payable pursuant to the Corlieve Sale and Purchase Agreement following the Corlieve Closing Date;”
​
2.3.The defined term “Permitted Investment” set forth in Section 1.1 of the Loan Agreement is hereby amended to insert the following clause (xiii) in appropriate numerical order as follows:
​
“(xiii) Investments permitted by Section 7.20(b).
​
2.4.Section 7.12 of the Loan Agreement is hereby amended and restated in its entirety as follows:
​
“Deposit Accounts. No Obligor shall maintain any Deposit Accounts (other than (i) accounts consisting of the proceeds from the Leasehold Financing so long as the aggregate amount in such accounts do not exceed $10,000,000, (ii) payroll, trust or escrow accounts (including any escrow account established in accordance with the terms of the Corlieve Sale and Purchase Agreement) and (iii) the Corlieve Operating Accounts so long as Corlieve Therapeutics has not failed at any time to satisfy any of the conditions set forth in clauses (a) and (b) of the definition of “Corlieve Operating Accounts”), or accounts holding Investment Property, except with respect to which Lender has an Account Control Agreement and/or a right of pledge (subject only to a Lien under clause (xii) of the definition of Permitted Liens); provided however, Obligor shall deliver a completed and executed Perfection Certificate, no later than 30 Business Days after the Restatement Date.”
​
2.5.Section 3.1(a) of the Loan Agreement is hereby amended and restated in its entirety as follows:
​
“(a) uniQure Holdings grants to Lender a first ranking right of pledge on its shares in Corlieve Therapeutics, uniQure Bio and uniQure IP;”
​
2.6.Section 7.15 of the Loan Agreement is hereby amended and restated in its entirety as follows:
​
“The revenue of Subsidiaries which are not Obligors shall not exceed €250,000 in the aggregate on an annual basis. The fair market value of the assets of Subsidiaries which are not Obligors, excluding the fair market value of the assets of Corlieve Therapeutics, shall not exceed €500,000 in the aggregate at any given time.”
​
2.7.Section 7 of the Loan Agreement is hereby amended to insert the following Section 7.20 in appropriate numerical order as follows:
​
““7.20 Covenants Regarding Corlieve Therapeutics.
​
​

3

(a)If requested by the Agent, uniQure Holdings shall promptly execute and deliver in favor of Lender a French-law pledge agreement in respect of the shares of Corlieve Therapeutics owned by uniQure Holdings together with such other related documents and filings as may be reasonably requested by the Agent to perfect or give the highest priority to Lender’s Lien on such shares (in each case in form and substance reasonably satisfactory to the Agent); provided that such additional steps shall in no event include the opening of a special bank account pledged as an accessory to the financial securities account holding the shares on Corlieve Therapeutics owned by uniQure Holdings.
​
(b)No Obligor shall be permitted to make any Investment in Corlieve Therapeutics or payment pursuant to the Corlieve Sale and Purchase Agreement other than (i) the transactions to be consummated on Corlieve Closing Date; (ii) Investments by any Obligor in Corlieve Therapeutics after the Corlieve Closing Date in an amount not to exceed €20,000,000 in the aggregate, the proceeds of which shall be used for research and development of the acquired Product (as defined in the Corlieve Sale and Purchase Agreement) and reasonably related activities or to make such payments in the ordinary course of business as are required to comply with applicable laws and regulations, including (for the avoidance of doubt) payment of taxes; provided that such Investments under this clause (ii) may not be made until such time as the aggregate amount on deposit in the Corlieve Operating Accounts on or about the Corlieve Closing Date decreases to an amount less than or equal to €2,500,000; and (iii) any other payments required to be made pursuant to the Corlieve Sale and Purchase Agreement (including the purchase of any Free Shares on the Free Share Transfer Date) after the Corlieve Closing Date in an aggregate amount not to exceed €50,000,000.”
​
2.8.Section 8.2 of the Loan Agreement is hereby amended to insert “Section 7.20(b)” after each reference to Section 7.19.
​
2.9.Schedule 1 of the Loan Agreement is hereby amended to add the following paragraph 4:
​
“4.Corlieve Therapeutics SAS, a société par actions simplifiée formed under the laws of France.”
​
2.10.Exhibit E of the Loan Agreement is hereby amended to add the following row at the end of the table set forth therein:
​
[****]
​
​

4

2.11.Each reference in the Loan Agreement to “this Agreement” and the words “hereof,” “herein,” “hereunder,” or words of like import, shall mean and be a reference to the Loan Agreement as amended by this Consent and Amendment (the “Amended Loan Agreement”).
​
3.BORROWER’S REPRESENTATIONS AND WARRANTIES. Borrower represents and warrants that:
​
3.1.Immediately upon giving effect to this Consent and Amendment (i) the representations and warranties contained in the Loan Documents are true, accurate and complete in all material respects except to the extent such representations and warranties relate to an earlier date, in which case they are true and correct in all material respects as of such date (in all cases without duplication of any standard(s) of materiality contained in the Loan Documents as to such representations and warranties) and (ii) no Event of Default has occurred and is continuing with respect to which Borrower has not been notified in writing by Agent or Lender;
​
3.2.Borrower has the corporate or other applicable company power and authority to execute and deliver this Consent and Amendment and to perform its obligations under the Amended Loan Agreement;
​
		3.3.
	[Reserved.]

​
3.4.The execution and delivery by Borrower of this Consent and Amendment and the performance by Borrower of its obligations under the Amended Loan Agreement have been duly authorized by all necessary corporate or other applicable company action on the part of Borrower;
​
3.5.Subject to any matters which are set out as qualifications or reservations as to matters of law of general application in the legal opinions delivered to the Lender pursuant to the Loan Agreement, this Consent and Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against it in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors’ rights; and
​
3.6.As of the date hereof, it has no defenses against the obligations to pay any amounts under the Secured Obligations. Borrower acknowledges that each of Agent and Lender has acted in good faith and has conducted in a commercially reasonable manner its relationships with Borrower in connection with this Consent and Amendment and in connection with the Loan Documents.
​
Borrower understands and acknowledges that each of Agent and Lender is entering into this Consent and Amendment in reliance upon, and in partial consideration for, the above representations and warranties, and agrees that such reliance is reasonable and appropriate.
​
4.LIMITATION. The amendments set forth in this Consent and Amendment shall be limited precisely as written and shall not be deemed (a) to be a waiver or modification of any other term or condition of the Loan Agreement or of any other instrument or agreement referred to therein or to prejudice any right or remedy which Agent and/or Lender may now have or may have in the future under
​
​

5

or in connection with the Amended Loan Agreement or any instrument or agreement referred to therein; or (b) to be a consent to any future amendment or modification or waiver to any instrument or agreement the execution and delivery of which is consented to hereby, or to any waiver of any of the provisions thereof. Except as expressly amended hereby, the Loan Agreement shall continue in full force and effect.
​
5.EFFECTIVENESS. This Consent and Amendment shall become effective upon the satisfaction of all the following conditions precedent (the date of satisfaction of all such conditions precedent, the “Third Amendment Effective Date”):
​
5.1.Amendment. Obligors, Agent and Lender shall have duly executed and delivered this Consent and Amendment to Lender.
​
5.2.UCC-3 Amendment. uniQure Holdings shall have caused to be duly filed, or shall have authorized Agent to duly file, an amendment to uniQure Holdings’ existing financing statement on file with the Recorder of Deeds for the District of Columbia updating the collateral description therein to include the shares of Corlieve Therapeutics.
​
5.3.Payment of Lender Expenses. Borrower shall have paid all reasonable and invoiced Lender expenses (including all reasonable and invoiced attorneys’ fees and reasonable expenses) incurred through the date of this Consent and Amendment in an amount not to exceed $50,000.
​
6.RELEASE.   In consideration of the agreements of Agent and each Lender contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Borrower, on behalf of itself and its successors, assigns, and other legal representatives, hereby to the extent possible under applicable law fully, absolutely, unconditionally and irrevocably releases, remises and forever discharges Agent and each Lender, and its successors and assigns, and its present and former shareholders, affiliates, subsidiaries, divisions, predecessors, directors, officers, attorneys, employees, agents and other representatives (Agent, Lenders and all such other persons being hereinafter referred to collectively as the “Releasees” and individually as a “Releasee”), of and from all demands, actions, causes of action, suits, covenants, contracts, controversies, agreements, promises, sums of money, accounts, bills, reckonings, damages and any and all other claims, counterclaims, defenses, rights of set-off, demands and liabilities whatsoever of every name and nature, known or unknown, suspected or unsuspected, both at law and in equity, which Borrower, or any of its successors, assigns, or other legal representatives may now or hereafter own, hold, have or claim to have against the Releasees or any of them for, upon, or by reason of any circumstance, action, cause or thing whatsoever which arises at any time on or prior to the day and date of this Consent and Amendment, for or on account of, or in relation to, or in any way in connection with the Loan Agreement, or any of the other Loan Documents or transactions thereunder or related thereto. Borrower understands, acknowledges and agrees that the release set forth above may be pleaded as a full and complete defense and may be used as a basis for an injunction against any action, suit or other proceeding which may be instituted, prosecuted or attempted in breach of the provisions of such release. Borrower agrees that no fact, event, circumstance, evidence or transaction which could now be asserted or which may hereafter be discovered shall affect in any manner the final, absolute and unconditional nature of the release set forth above.
​
7.COUNTERPARTS. This Consent and Amendment may be signed in any number of counterparts, and by different parties hereto in separate counterparts, with the same effect as if the signatures to each such counterpart were upon a single instrument. All counterparts shall be deemed an original of this Consent and Amendment. This Consent and Amendment may be executed by facsimile, portable document format (.pdf) or similar technology signature, and such signature shall constitute an original for all purposes.
​

6

8.INCORPORATION BY REFERENCE. The provisions of Section 10 (Miscellaneous) of the Loan Agreement shall be deemed incorporated herein by reference, mutatis mutandis.
​
9.        LOAN DOCUMENTS. This Consent and Amendment shall constitute a Loan Document. 
​
[Remainder of this page intentionally left blank]
​
​

7

IN WITNESS WHEREOF, the parties have duly authorized and caused this Consent and Amendment to be executed as of the date first written above.
​
	​
	BORROWERS:

	​
	​

	​
	UNIQURE BIOPHARMA B.V.

	​
	​
	​

	​
	Signature:
	/s/ Christian Klemt

	​
	Print Name:
	Christian Klemt

	​
	Title:
	Chief Financial Officer, Director

​
	​
	UNIQURE, INC.

	​
	​
	​

	​
	Signature:
	/s/ Matt Kapusta

	​
	Print Name:
	Matt Kapusta

	​
	Title:
	Chief Executive Officer

​
	​
	OBLIGORS:

	​
	​
	​

	​
	UNIQURE N.V. (formerly uniQure B.V.)

	​
	​
	​

	​
	Signature:
	/s/ Matt Kapusta

	​
	Print Name:
	Matt Kapusta

	​
	Title:
	Chief Executive Officer

​
	​
	UNIQURE IP B.V.

	​
	​
	​

	​
	Signature:
	/s/ Matt Kapusta

	​
	Print Name:
	Matt Kapusta

	​
	Title:
	Chief Executive Officer

​
​

Signature Page to Consent and Amendment No. 3 to Loan and Security Agreement

Accepted in Palo Alto, California:
​
	​
	AGENT:

	​
	​

	​
	HERCULES CAPITAL, INC.

	​
	​
	​

	​
	By:
	/s/ ****

	​
	Name:
	****

	​
	Its:
	Associate General Counsel

​
	​
	LENDER:

	​
	​

	​
	HERCULES CAPITAL FUNDING TRUST 2018-1

	​
	​
	​

	​
	By:
	/s/ ****

	​
	Name:
	****

	​
	Its:
	Associate General Counsel

​
	​

	​

	​

	​
	HERCULES CAPITAL FUNDING TRUST 2019-1

	​
	​
	​

	​
	By:
	/s/ ****

	​
	Name:
	****

	​
	It:
	Associate General Counsel

​

Signature Page to Consent and Amendment No. 3 to Loan and Security AgreementEX-10.1

 Exhibit 10.1 
  

 
 One Sansome St. 33rd FloorSan 

Francisco, CA 94104 
 hr@wish.com 

October 7, 2021 
 VIA EMAIL 

Ying (Vivian) Liu 
 Dear Vivian: 

Contextlogic Inc. (the “Company” or “Wish”) is pleased to offer you employment in our San Francisco office, on the
following terms: 
  

	1.	 Position and Start Date. Your title will be Chief Financial Officer. In this role, you will report to
the Company’s Chief Executive Officer and you will be expected to perform such duties and exercise such responsibilities as are assigned from time-to-time. In
carrying out these duties and responsibilities, you shall comply with all policies, procedures, rules and regulations, both written and oral, as are provided by the Company from
time-to-time, and carry out said duties and responsibilities in a diligent, faithful and honest manner. Your employment start date with the Company is currently
October 25, 2021. You may delay your employment start date for up to three (3) weeks from October 25, 2021 if necessary to transition out of your current employment and if you provide written notice to the Company on your intention to
delay your start date by no later than October 15, 2021. Your employment start date with the Company will also be your appointment date for external reporting purposes. This is a full-time position. 

 

	2.	 Compensation. The Company will pay you a starting base salary of $550,000 per year, payable in
accordance with the Company’s standard payroll schedule. This salary will be subject to adjustment pursuant to the Company’s employee compensation policies and procedures in effect from time to time. 

 

	3.	 Signing Bonus: This offer includes a signing bonus in the amount of $425,000, which will be paid to you
within 90 days of your start date. If you voluntarily resign or are terminated for cause (as defined in the Executive Severance and Change in Control Agreement, as further described below) from the Company before the
one-year anniversary of your start date, you agree to repay the Company the full net amount of the signing bonus within 30 days of your separation date. 

 

	4.	 Employee Benefits. As a regular employee of the Company, you will be eligible to participate in a number
of Company-sponsored benefits, including our group health insurance plan, in accordance with the applicable plan documents and policies. The Company reserves the right to modify or discontinue such benefit plans in its sole discretion. In addition,
you will be eligible to participate in the Company’s paid time off policy, as in effect from time to time. A copy of the current paid time off policy will be provided to you upon hire and any subsequent versions will be posted on the
Company’s wiki/intranet. 

	5.	 Restricted Stock Units. Subject to the approval of the Company’s Board of Directors or its
Compensation Committee, you will be granted the awards of Restricted Stock Units (“RSUs”) identified below. The RSUs will be subject to the terms and conditions applicable to RSUs granted under the Company’s 2020 Equity Incentive Plan
(the “Plan”), as amended, your Notice of Restricted Stock Unit Award, and the applicable Restricted Stock Unit Agreement, which will all be distributed to you as soon as practicable after your employment start date and the RSU grant date.

  

	 	(a)	 Inducement Grant. An “Inducement Grant” award of 2,950,311 RSUs. The RSUs will vest over time
based on your continuous service with the Company, with the first 1116th of the RSUs vesting on February 15, 2022. An additional 1/16th of the remaining RSUs will vest on each Company Vesting Date thereafter, provided that you remain in
continuous service through each such Company Vesting Date. A “Company Vesting Date” means February 15th, May 15th, August 15th, or November 15th. 

  

	 	(b)	 Make-Whole Grant. A “Make-Whole Grant” award of 329,969 RSUs. The RSUs will vest in four
(4) equal quarterly installments, based on your continuous service with the Company, with the first 114th of the RSUs vesting on February 15, 2022. An additional 114th of the RSUs will vest on each Company Vesting Date thereafter, provided
you remain in continuous service through each such Company Vesting Date. A “Company Vesting Date” means February 15th, May 15th, August 15th, or November 15th. 

 

	6.	 Transportation Reimbursement. The Company will reimburse you for the reasonable expenses incurred by you
for taking a car service to and from our San Francisco office for up to two (2) days a week, subject to you providing receipts of such service and submitting such receipts in accordance with the Company’s Expense Reimbursement Policy.

  

	7.	 Executive Severance and Change in Control. Attached as Exhibit A is the Executive Severance and
Change in Control Agreement, pursuant to which you will be eligible for certain severance and acceleration benefits in connection with certain qualifying terminations of your employment with the Company. 

 

	8.	 Confidential Information and Invention Assignment Agreement. Like all Company employees, you will be
required, as a condition of your employment with the Company, to sign the Company’s standard Confidential Information and Invention Assignment Agreement, a copy of which is attached hereto as Exhibit B. We also want to make clear that we
do not want you to, and we hereby direct you not to, bring with you any confidential or proprietary information of any former employer or other entity or to violate any other obligations you may have to any former employer or other entity. By
signing this agreement, you confirm to the Company that you have no contractual commitments or other legal obligations that would prevent you from performing your duties for the Company. 

 

	9.	 Conflicts of Interest. During your employment, you agree not to engage in any employment, business, or
activity that is in any way competitive with the business or proposed business of the Company, which materially interferes with the performance of your job duties, or creates a conflict of interest (this includes any other full-time employment
arrangements); provided, however, that you may continue to provide services and/or continue to engage in the current business activities that you list on Exhibit C hereto during your employment with the Company. During your employment with
the Company, you may request (and submit to Wish for approval) an Outside Activity Disclosure Form from hr@wish.com to disclose any other outside employment, business, or activity in which you intend to engage during employment with Wish.
Failure to make disclosures is considered a material representation that you are not engaged or associated with any such outside activities at the beginning of employment. You will be responsible for complying with Wish’s Conflict of Interest
Policy, including updated disclosures of such outside activities, at all times during employment. 

	10.	 Employment Relationship. Employment with the Company is at-will.
This means that you have the right to resign and the Company has the right to terminate your employment at any time, for any or no reason, with or without cause, and with or without notice. Any contrary representations that may have been made to you
are superseded by this letter agreement. This, along with the Confidential Information and Invention Assignment Agreement, is the full and complete agreement between you and the Company on this term. Although your job duties, title,
responsibilities, compensation and benefits, as well as the Company’s personnel policies and procedures, may change from time to time, the “at will” nature of your employment may only be changed in an express written agreement signed
by you and the CEO of the Company. 

  

	11.	 Tax Matters. 

  

	 	(a)	 Withholding. All forms of compensation referred to in this letter agreement are subject to reduction to
reflect applicable withholding and payroll taxes and other deductions required by law. 

  

	 	(b)	 Tax Advice. You are encouraged to obtain your own tax advice regarding your compensation from the
Company. You agree that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or its Board of Directors related to tax liabilities
arising from your compensation. 

  

	12.	 Interpretation, Amendment and Enforcement. This letter agreement and the accompanying exhibits,
including the Confidential Information and Invention Assignment Agreement, along with documents related to your equity grants, constitute the complete agreement between you and the Company, contain all of the terms of your employment with the
Company and supersede any prior between you and the Company. This letter agreement may only be amended by an authorized officer of the Company. 

  

	13.	 Arbitration of Disputes. The Company and I mutually consent to the resolution by arbitration, under the
applicable rules of JAMS (which are available at jamsadr.com, or from the Company upon my request), of all claims (common law or statutory) that the Company might have against me, or that I may have against the Company, its affiliated
companies, the directors, employees or agents of any such company, and all successors and assigns of any of them. The Company and I waive the right to have a court or jury trial on any arbitrable claim. The Federal Arbitration Act shall govern this
arbitration agreement, or if for any reason the FAA does not apply, the arbitration law of the state in which I rendered services to the Company. Notwithstanding any provision of the JAMS Rules, arbitration shall occur on an individual basis only,
and a court of competent jurisdiction (and not an arbitrator) shall resolve any dispute about the formation, validity, or enforceability of any provision of this arbitration agreement. I waive the right to initiate, participate in, or recover
through, any class or collective action. To the maximum extent permitted by law, the arbitrator shall award the prevailing party its costs and reasonable attorney’s fees; provided, however, that the arbitrator at all times shall apply the law
for the shifting of costs and fees that a court would apply to the claim(s) asserted. Nothing in this arbitration agreement prevents me from filing or recovering pursuant to a complaint, charge, or other communication with any federal, state or
local governmental or law enforcement agency. This arbitration agreement shall remain in effect notwithstanding the termination of my association with the Company. To opt-out of this paragraph, you must
complete an opt-out form prior to your start date. Please email hr@wish.com for the form. 

	14.	 Contingencies. This offer is contingent upon proof of identity and work eligibility, which must be
submitted to the Company within 72 hours of your start date. Your continued employment with the Company is contingent upon you remaining authorized to work in the United States for Wish. The Company reserves the right to conduct background, credit
and/or reference checks on all of its potential employees. Your job offer, therefore, is contingent upon clearance of such background, credit and/or reference checks, including satisfactory responses to a D&O questionnaire.

 We hope that you will accept our offer to join the Company. You may indicate your agreement with these terms and accept
this offer by signing and dating this letter agreement and the enclosed exhibit, and returning them to me. This offer, if not accepted, will expire at the end of the day on October 8, 2021. 

 
  

	
	 Very truly yours,
  

CONTEXTLOGIC INC.
  

/s/ Piotr Szulczewski
  

Piotr Szulczewski
 CEO

 
 10/19/2021

 Enclosures 

 I have read and accept this employment offer: 

Name    Ying (Vivian) Liu 
 Signature 

/s/ Ying (Vivian) Liu 
 Date
(MM/DDMYYY)    10/7/2021

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}]]